Goldman Sachs’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
– Sell
-373,720
Closed -$22.3M – 5654
2020
Q2
$22.3M Buy
373,720
+264,365
+242% +$16.3M 0.01% 1592
2020
Q1
$6.49M Buy
109,355
+48,341
+79% +$2.82M ﹤0.01% 2427
2019
Q4
$3.34M Buy
61,014
+31,429
+106% +$1.17M ﹤0.01% 3261
2019
Q3
$836K Buy
29,585
+21,453
+264% +$787K ﹤0.01% 4148
2019
Q2
$270K Buy
8,132
+105
+1% +$3.28K ﹤0.01% 4659
2019
Q1
$273K Sell
8,027
-4,226
-34% -$134K ﹤0.01% 4676
2018
Q4
$336K Sell
12,253
-65,643
-84% -$1.69M ﹤0.01% 4582
2018
Q3
$2.28M Buy
+77,896
New +$2.2M ﹤0.01% 3514

Other funds holding PRNB

Goldman Sachs's PRNB Position: Q3 2020 in Review

Goldman Sachs sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q3 2020, closing a stake of 373,720 shares — an estimated $22.3M sold.

Goldman Sachs first reported a position in PRNB in Q3 2018 and held it in 8 quarters. The position peaked at $22.3M in Q2 2020. 9 funds tracked by Wall St. Rank hold PRNB as of Q3 2020.

  • Goldman Sachs reported no remaining Principia Biopharma Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Goldman Sachs sold 373,720 Principia Biopharma Inc. Common Stock shares in Q3 2020, an estimated $22.3M.
  • Goldman Sachs first reported a position in Principia Biopharma Inc. Common Stock in Q3 2018 and held it in 8 quarters.
  • Goldman Sachs's Principia Biopharma Inc. Common Stock position peaked at $22.3M in Q2 2020.
  • 9 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q3 2020.

Based on Goldman Sachs's 13F filing for Q3 2020, filed 13 Nov 2020.